Compared with non-DM patients, DM patients treated with GLP-1 RA/SGLT-2i had an almost 30% increased risk of the primary endpoint, while DM patients not treated with GLP-1 RA/SGLT-2i had an almost 60% increased risk (Fig. 3). This evidence concerns the gene GLP1R and diabetes mellitus.